Cingulate Stock
Cingulate Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Shane J. Schaffer
- Employees
- 14
- Market cap
- $63 M
- IPO
- 08/12/2021
Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase…
Cingulate stock: price history
1D
-0.7%
1W
-10.8%
1M
-14.3%
6M
-20.0%
YTD
+0.5%
1Y
+14.7%
2Y
-0.9%
5Y
–
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~107% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Cingulate
Analyst assessment of Cingulate
PRICE TARGET LOW
US$9.00
CONSENSUS
US$9.00
MEDIAN
US$9.00
PRICE TARGET HIGH
US$9.00
0
STRONG BUY
5
BUY
1
HOLD
0
SELL
0
STRONG SELL
6
TOTAL · Buy
As of: 24/08/2026
Cingulate stock metrics
P/E
-0.87
P/B
1.01
EV/EBITDA
-1.67
RETURN ON EQUITY
-25.0%
NET MARGIN
0.0%
DEBT/EQUITY
0.27
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
83.5%
FLOAT SHARES
12,137,859
AVG. DAILY VOLUME (30D)
97,181
Insider transactions (SEC)
Hargroves Thomas Jeffrey
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Cingulate stock
What does Cingulate do?
Cingulate Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Shane J. Schaffer, the company employs around 14 people.
The IPO was on 08/12/2021; the stock trades on NASDAQ under the ticker CING.
What do analysts say about Cingulate stock?
6 analysts rate the stock, the consensus is Buy (as of 24/08/2026).
The average price target is US$9.00, ranging from US$9.00 to US$9.00, with a median of US$9.00.
This is an external assessment, not a statement by Market Jury.
When does Cingulate report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 107% stronger than usual.
Does Cingulate pay a dividend?
No, Cingulate currently does not pay a dividend.
Which stocks are comparable to Cingulate?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Cingulate stock analyzed?
Clicking "Analyze stock" lets five strategies assess Cingulate against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.